Skip to main content
Premium Trial:

Request an Annual Quote

Foundation Medicine Partners with Sanofi to Identify Biomarkers for Cancer Drugs

Premium

Foundation Medicine said this week that is has inked a strategic collaboration with Sanofi for cancer biomarkers.

Under the agreement, the Cambridge, Mass.-based company will use its genomic sequencing and analysis expertise to identify genetic biomarkers and potential companion diagnostics for certain oncology drug candidates from Sanofi.

The partnership with Sanofi adds to four other collaborations Foundation has established with pharmaceutical firms, including Johnson & Johnson Pharmaceutical Research and Development, Novartis, and Celgene.

In addition to these alliances, Foundation Medicine is working on a diagnostic cancer genomic test, which uses next-generation sequencing to analyze about 200 cancer-related genes in clinical-grade tumor tissues (CSN 6/8/2011).

Last fall, the company raised $33.5 million in a Series A financing round to support the commercialization of the test, which it plans to launch in the second quarter of this year.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.